Posts Tagged ‘pharmaceutical sales’

Brand New Opportunity – Hospital Sales Representative – Specialist IV Hospital Products – OTE £60k+ – North East, East Midlands, England

February 17, 2012

Hospital Sales Specialist – Basic to £45k, OTE £60k++
An opportunity to develop your talents working for a leading global Healthcare Company. Our client is currently looking for a Sales Specialist to develop the business in key hospital accounts throughout the North East, Yorkshire and East Midlands. Although a large geographical area this is a focused and targeted role with an emphasis on key account management.

This organisation has built an enviable portfolio of products and services that push back the frontiers of medical care and ultimately ensuring a better quality of life for people everywhere.

This opportunity for a Sales Specialist is an integral part of a specialty sales team reporting to the National Sales & Marketing Manager. You would be fully supported by internal functions such as marketing, customer services, logistics and shared services; YOU would be the interface of the company and the customer. With a drive for increased Patient Safety, in the NHS, when administering medication, our client is an excellent position to develop partnerships in hospital trusts. This role will involve selling new  as well as some established products and services.

Key responsibilities would include:
– Developing and implementing appropriate strategies for agreed customer targets with the objective of driving sales results and achieving or exceeding budgets.
– To identify key finance and clinical decision makers within Consortia, Hospitals and Units and arrange meetings to promote relevant products and services
– Gathering intelligence on customer plans and purchasing intentions and recommend responsive, timely and appropriate action.
– Maintaining a high level of knowledge of the therapy area and related products
– In conjunction with the National Sales Manager and wider commercial management team, provide informed input into/manage the tender process.
– Calling on key customers as per your business plan (Clinical/Aspectic/Purchasing Pharmacists, Procurement, Clinicians, Specialist Nurses)

To be considering for this exciting opportunity you are likely to have
– Previous hospital sales experience (2 years)
– Knowledge/Experience of NHS structure & buying processes
– Life sciences degree, nursing qualification, business degree (or equivalent experience in UK healthcare market for minimum of 2 years)
– ABPI qualification and/or willing to study if required.

In return for your expertise if successful you will be offered a competitive salary & excellent benefits package including an uncapped bonus scheme. You will also receive first rate training and ongoing development.

To discuss this role in more detail please contact us on 0845 026 2020 or alternatively please submit your details by emailing administrator@2020selection.co.uk

Advertisements

NICE to review local formularies to end post-code prescribing lottery

February 7, 2012

NICE is to produce a best practice guide to help trusts develop local formularies, as part of a move to ensure that all patients in England have access to clinically and cost-effective drugs.

Local formularies provide a list of selected or preferred drugs available to local prescribers and have an important role in underpinning safe and effective use of medicines.

However, there is currently no standard process or advice for putting together a local formulary which has led to variations across the country.

Medicines Management departments within many PCTs currently operate a controversial traffic light sytem of red lists and green lists, which does not necessarily reflect NICE guidance.

A recent report into innovation in healthcare by The Department of Health has highlighted that not all local formularies are including all of NICE’s technology appraisals. This can lead to a postcode lottery where patients miss out on drugs approved by NICE.

In some cases, local formularies are duplicating NICE assessments and challenging appraisal recommendations, acting as a barrier to the uptake of NICE-approved medicines.

The report states that the Department of Health is “committed to ensuring that NHS patients have access to clinically and cost-effective drugs and technologies, and that NICE appraisal guidance is promptly delivered throughout the NHS.

“There should be no local barriers to accessing technologies recommended in NICE appraisals, beyond a clinical decision relating to an individual patient.”

The report recommends that formulary processes should proactively consider the impact of new NICE Technology Appraisals, and all NICE Technology Appraisal recommendations should – where clinically appropriate – be automatically incorporated into local formularies.

This process should take place within 90 days to support compliance with the three month funding direction and the NHS Constitution ensuring that these medicines are available for clinicians to prescribe, should they choose to, in a way that supports safe and clinically appropriate practice.

To help achieve this, NICE will develop a best-practice guide covering the creation and review of local formularies to assist local trusts and clinical commissioning groups.

Dr Gillian Leng, Deputy Chief Executive of NICE said: “NICE will embark on a specific piece of work to look at how local formularies are put together. At the moment there is no standard process for them and there tends to be a lot of variation and inconsistencies across England. This has been flagged up in the recent NHS Innovation report.

“NICE will produce a best-practice guide on how to develop a local formulary. We will be holding a workshop to develop the guide, which will then go out to consultation before being published later this autumn.”

“NICE-approved drugs should not be excluded from local formularies on the grounds of cost. We want all patients to have access to medicines that we consider to be effective,” added Dr Leng.
Elsewhere, the report outlines plans to introduce, within three months, a NICE Compliance Regime for the funding direction attached to NICE technology appraisals to ensure rapid and consistent implementation throughout the NHS.

The Department of Health will also establish a NICE Implementation Collaborative (NIC) to support the implementation of NICE guidance. The NIC will bring together the NHS Commissioning Board, NICE, the Chief Pharmaceutical Officer, the main industry bodies, the NHS Confederation, the Clinical Commissioning Coalition and the Royal Colleges.

Reference: http://www.nice.org.uk/

20:20 Selection is a specialist recruitement agencies which places candidates into roles within the UK pharmaceutical and healthcare/devices sales industries. The agency has been established since 2002. If you are seeking a role within pharmaceutical sales please visit our website to view our live vacancies http://www.2020selection.co.uk

GP/Hospital Representative – North West England – Superb Opportunity…Hurry As This Will Go Quickly!

February 2, 2012

We are seeking an experienced Medical Sales Representative (GP/Hospital) to cover the Lancashire and Cumbria territory working for a global leader in healthcare.

This is an opportunity for you to take control of your business results; the successful person will be charged with maximising sales across this territory for a portfolio of prescription products selling to General Practitioners, Hospital Customers, other relevant HCP’s and retail pharmacies throughout the territory.

To be considered for this position you will have the following skills/abilities:
– Commercial background and a good understanding of Key Account Management
– Strong team working will be important as you will have to work effectively with your customers and NHS Liaison Managers
– Preferably educated to degree level or equivalent.
– Proven track record of sales success
– Strong commercial awareness coupled with an in depth understanding of the key stakeholders within the NHS
– Flexibility and adaptability to operate in dynamic working environment
– Be accountable for own work load/decision making and actions
– Results orientated (set personal goals)
– Impact, enthusiasm and self motivated coupled with drive and determination to succeed

In return for your skills and contacts this organisation will offer the successful person a comprehensive salary & benefits package (basic salary is commensurate with experience) plus ongoing development throughout their career. Want to know more? Call us now on 0845 026 2020 or submit your CV here. This opportunity does have the potential to move quickly.

20:20 Selection Ltd promises to treat your application as important and will review your profile against our client’s requirements. However, if you have not heard from us within 7 days please assume that on this occasion you have not been successful. There are many more opportunities like this one advertised on our website daily……all our jobs are live
Visit http://www.2020selection.co.uk/ to learn more……it’s free

Global Top Ten Pharma Company based in SE England recruiting for a Training Manager

February 1, 2012

This is just one of many live vacancies that are being advertised by 20:20 Selection. Please visit the website to see all these exciting opportunities in the UK Pharmaceutical Industry.

Training Manager, specialist products division within the pharmaceutical business of a global healthcare company.

An opportunity currently exists for a talented training and development manager to be responsible for delivering programmes in line with agreed company training strategy. You will focus on specialist therapy areas such as renal and neurology (Parkinson Disease). Additionally you would also be the point of contact point and coordinator, for the UK implementation of the E-Learning strategy

This is a Head Office based role (Berkshire) requiring you to work cross functionally with marketing, medical and sales management in order to offer the highest quality training solutions, your responsibilities will include:
– Coordinating and running induction/initial training
– Providing ongoing support across the franchise for new campaigns, conference etc.
– Working with brand teams to identify desired training outcomes that will support brand plan execution
– Supporting growth plans within division and working with other Training Managers to develop and deliver training plans
– Annual planning, ensuring adherence to budget and deadlines.
 
To be considered for this exciting position you are likely to:
– Have healthcare related sales experience having demonstrated achievements in sales & your career to date
– Have some prior training experience with a training qualification being an advantage
– Show potential to be innovative and creative in approach to both the design and delivery of training programmes
– Demonstrate good coaching and counselling skills
– Possess well-developed interpersonal skills with the adaptability to work cross-functionally within the company
– Have excellent planning skills with the drive to see projects through to completion
– Be able to work well under pressure & have a high level of flexibility.
It is likely that you are educated to degree level and are ideally ABPI qualified.

On offer to the successful person will be a highly competitive basic salary and benefits package. This is a superb opportunity to join a forward thinking team in a company who truly believe in investing in people.

Please don’t delay in applying. Email your CV to administrator@2020selection.co.uk and/or call on of our recruitment consultants on 0845 026 2020.

New Role Just In – Hospital Sales Specialist ( NE, Yorks, East Mids)

January 31, 2012

Hospital Sales Specialist – Basic to £45k, OTE £60k++

Many more live vacancies can be viewed at http://www.2020selection.co.uk

An opportunity to develop your talents working for a leading global Healthcare Company. Our client is currently looking for a Sales Specialist to develop the business in key hospital accounts throughout the North East,YorkshireandEast Midlands. Although a large geographical area this is a focused and targeted role with an emphasis on key account management.

This organisation has built an enviable portfolio of products and services that push back the frontiers of medical care and ultimately ensuring a better quality of life for people everywhere.

This opportunity for a Sales Specialist is an integral part of a specialty sales team reporting to the National Sales & Marketing Manager. You would be fully supported by internal functions such as marketing, customer services, logistics and shared services; YOU would be the interface of the company and the customer. With a drive for increased Patient Safety, in the NHS, when administering medication, our client is an excellent position to develop partnerships in hospital trusts. This role will involve selling new  as well as some established products and services.

Key responsibilities would include:

– Developing and implementing appropriate strategies for agreed customer targets with the objective of driving sales results and achieving or exceeding budgets.

– To identify key finance and clinical decision makers within Consortia, Hospitals and Units and arrange meetings to promote relevant products and services

– Gathering intelligence on customer plans and purchasing intentions and recommend responsive, timely and appropriate action.

– Maintaining a high level of knowledge of the therapy area and related products

– In conjunction with the National Sales Manager and wider commercial management team, provide informed input into/manage the tender process.

– Calling on key customers as per your business plan (Clinical/Aspectic/Purchasing Pharmacists, Procurement, Clinicians, Specialist Nurses)

To be considering for this exciting opportunity you are likely to have

– Previous hospital sales experience (2 years)

– Knowledge/Experience of NHS structure & buying processes

– Life sciences degree, nursing qualification, business degree (or equivalent experience inUKhealthcare market for minimum of 2 years)

– ABPI qualification and/or willing to study if required.

In return for your expertise if successful you will be offered a competitive salary & excellent benefits package including an uncapped bonus scheme. You will also receive first rate training and ongoing development.

To discuss this role in more detail please contact us on 0845 026 2020 or alternatively please submit your details by emailing administrator@2020selection.co.uk

20:20Selection Ltd promises to treat your application as important and will review your profile against our client’s requirements. However, if you have not heard from us within 7 days please assume that on this occasion you have not been successful.

Trainee Recruitment Consultant – A Day In The Life Of Chris

January 26, 2012

Last week I started a training contract within an established Medical Sales recruitment company  As a virgin to the industry I prepared myself as best I could for what I was about to undertake. I did all my reading around the career area and the company itself and eventually it came down to taking the plunge and accepting a 2 week trial in a very unpredictable time period for a recruitment consultant, the 2 weeks preceding the Christmas break. This is obviously an odd time in the industry as our Clients will be in one of 2 camps, the 1st of which being the “lets get the most out of our budget spend before the end of the year before its taken away from us in January”, and the 2nd being, “I’ve done all I can this year, lets start again in 2012”.

My 1st day was, as expected, the birth by fire. This is how we operate, take in as much as you can and see if you can keep up. This gave me a great insight into the speed, efficiency, and accuracy required from a consultant. If you’re not 1st, you’re last. This ethos opens up possibilities for huge success but at the same time great falls. After all we are competing against several other companies with differing approaches to achieving the same goal, luckily for me I’m working on the basis of quality rather than quantity. But that doesn’t mean quantity doesn’t get it right some times.

The harsh reality of the other side of recruitment fast became apparent. You really have to shine to get noticed in the current climate and the vast array of approaches that candidates use to attain this is eye opening. The role itself is very diverse. Admin is air tight, and has to be. It can be the difference between placing and missing out, a point regularly re-enforced during my training thus far. Combine admin with confident selective telephone manner, excellent knowledge of your clients and candidates, and the foresight to combine the two and you may have what it takes to take on the world of recruitment.

The industry requires you to effectively sit on a knife edge, the whole game is in balance, continually changing as both clients and candidates change their ‘requirements’, which can either push you right to the top or plunge you back to square one. This makes for a very exciting work environment as we are challenged with the task of keeping the balance in our favour right until the very last minute and then if all goes to plan, we can tip the scales and reap the benefit.

The team currently have the task of not only managing business but also managing me. As a fresh starter I am as keen and eager as you’d expect. I want to get my hands dirty and dive straight in but my lack of experience leaves me blind to the consequence. I am effectively stood on top of a diving board blindfold, trusting my team for direction and timing so I land on soft success rather than the hard ground of misconception. Time will tell……

Which Recruitment Agency?

January 18, 2012

Despite the global recession and credit crunch, one of the UK’s leading pharmaceutical recruitment agencies , 20:20 Selection Ltd has gone from strength to strength. How have they acheived their organic growth in these difficult times?

The team have over 50 years of combined, actual experience in the pharmaceutical and healthcare sales arenas in the UK.

Managing Director Karen Forshaw formed the company in 2002, after a successful career in medical sales (both primary and secondary care) and medical sales management (at both area and national sales manager level). She is passionate about providing an unirivaled service to both clients and candidates. The 20:20 Selection maxim of “perfect vision: not hindsight” extols the company virtues down to a tee. By carefully selecting their  candidates, 20:20 Selection ensure that when one goes before a client for an interview then they have an excellent chance of actually getting hired.

Using the experience and advice from Karen’s team, 20:20 Selection will ensure that you are only ever put forward for roles which you really understand and want to do. They only send your CV to clients with your full permission. Should you get an interview, then Karen and the team will keep you fully briefed and ‘prepped’ during the entire process. They have an enviable reputation within the industry as a recruitment company that really cares about both clients and candidates. One of the prime motivating factors is that individual consultants are not bonussed on just their own performance, but on the performance of the whole company. As a result you will not find yourself being forced or coerced into going for a role just to make up the sales figures of the consultant that you are dealing with.

So if you are interested in a role in UK pharmaceutical, medical or device sales then please contact us at administrator@2020selection.co.uk or visit our website http://www.2020selection.co.uk to find out more about the company.

Please note that in order to reach our minimum standards you will need to be qualified to work in the UK, have a full UK driving licence with not more than 6 points and be educated to degree level or be of graduate calibre.

Good Luck in your career.

Monoclonal Antibodies

January 3, 2012

MABS / CYTOKINE MODULATORS / ANIT- TNF AGENTS AND MORE

 

A medication ending with the stem ‘mab’ indicates that it is a monoclonal antibody. This is the internationally recognised nomenclature for the naming of monoclonal antibodies.

Nomenclature has become somewhat confusing though as the BNF includes ‘mabs’ under the heading of cytokine modulators and anti-lymphocyte monoclonal antibodies in several chapters.

Monoclonal antibody production for medical use was first discovered by Milstein and Kohler in 1975, but it was confined mainly to diagnostics until Vilcek and Li approached Centacor (now part of Johnson & Johnson) to help them produce ‘mabs’ against TNFα.

Tumour necrosis factor-alpha (TNFα) is a cytokine (an immunomodulating agent) produced by monocytes and macrophages, two types of white blood cells. It mediates the immune response by increasing the transport of white blood cells to sites of inflammation, and through additional molecular mechanisms which initiate and amplify inflammation. Inhibition of its action by ‘mabs’ reduces the inflammatory response which is especially useful for treating autoimmune diseases.

The ‘mab’ that Vilcek and Li discovered become known as Infliximab (Remicade) and it became an important treatment for severe Crohn’s disease, including the fistulating variety. It has subsequently been used to treat other auto-immune system  diseases such as psoriasis and rheumatoid arthritis. Infliximab became known as ‘Kwik Fiximab’ in medical circles due to it’s clinical success in treating otherwise unresposive patients.

There are two types of TNF receptors: those found embedded in white blood cells that respond to TNF by releasing other cytokines, and soluble TNF receptors which are used to deactivate TNF and blunt the immune response. In addition, TNF receptors are found on the surface of virtually all nucleated cells. Red blood cells, which are not nucleated, do not contain TNF receptors on their surface.

A ‘mab’ neutralises the biological activity of TNFα by binding with high affinity to the soluble (free floating in the blood) and transmembrane (located on the outer membranes of T cells and similar immune cells) forms of TNFα and inhibits or prevents the effective binding of TNFα with its receptors. Infliximab and adalimumab (another TNF antagonist) are in the subclass of “anti-TNF antibodies” (they are in the form of naturally occurring antibodies), and are capable of neutralising all forms (extracellular, transmembrane, and receptor-bound) of TNFα. Etanercept, a third TNF antagonist, is not a ’mab’ and it is in a different subclass (receptor-construct fusion protein), and, because of its modified form, cannot neutralize receptor-bound TNFα. Etanercept is sometimes referred to as a ‘non-biologial’ agent to distinguish it further from the ‘mabs’ Additionally, the anti-TNF antibodies adalimumab and infliximab have the capability of lysing cells involved in the inflammatory process, whereas the receptor fusion protein apparently lacks this capability. Although the clinical significance of these differences have not been absolutely proven, they may account for the differential actions of these drugs in both efficacy and side effects.

Infliximab has high specificity for TNFα, and does not neutralise TNF beta (TNFβ, also called lymphotoxin α), an unrelated cytokine that uses different receptors from TNFα. Biological activities that are attributed to TNFα include: induction of proinflammatory cytokines such as interleukin (IL) 1 and IL 6, enhancement of leukocyte movement or migration from the blood vessels into the tissues by increasing the permeability of endothelial layer of blood vessels; and increasing the release of adhesion molecules.

A range of newer agents which act against these other cytokines have subsequently been developed.

Tha table below summarises the anti- TNF mabs available in the UK currently. None-mab anti-TNF agents are also included for comparison

MOLECULE BRAND CLASS DERIVATION INDICATION NICEAPPROVED
Adalimumab Humira (Abbott) Anti-TNFα Recombinant human ‘mab’From hamster ovary RAPJIA

PA

AS

CD

P

 

YesNo

Yes

Yes

Yes

Yes

Anakinra Kineret (Swedish Orphan) Anti-IL-1 Recombinant human ‘mab’From E Coli RA No 
Alemtuzumab MabCampath (Genzyme) Anti-lymphocyte Recombinant human ‘mab’ from hamster ovary CLL Yes 
Certolizumab Pegol Cimzia (UCB Pharma) Anti-TNFα Recombinant human ‘mab’From E Coli RA Yes
Golimumab Simponi (Schering-Plough)  Anti-TNFα Recombinant human ‘mab’ from murine cell line RAPA

AS

YesNo

No

Infliximab Remicade (Schering-Plough) Anti-TNFα Recombinant human ‘mab’ RACD

UC

AS

PA

P

 

YesYes

Yes

Yes

Yes

Yes

 

Ofatumumab Arzerra (GSK) Anti-lymphocyte Recombinant human ‘mab’ from murine cell line CLL No
Rituximab MabThera (Roche) Anti-TNFα Recombinant human ‘mab’ from hamster ovary RACLL

NHL

 

YesYes

Yes

 

Tocilizumab RoActemra (Roche) Anti-IL-6 Recombinant human ‘mab’ from hamster ovary RA Yes 
Ustekinumab Stelara (Janssen-Cilag) Anti-IL-12/23 Recombinant human ‘mab’ from murine cell line P Yes 
           
Abatacept Orencia (Bristol-Myers Squibb) T-cell modulator Fused protein formed by recombinantDNAtechnology RAPJIA YesNo

 

Etanercept Enbrel (Wyeth) Anti-TNFα(soluble receptor specific) Fused protein formed by recombinantDNAtechnology from hamster ovary RAPJIA

PA

AS

P

 

YesYes

Yes

Yes

Yes

 

KEY

RA = Rheumatoid arthritis

PJIA = Polyarticular juvenile idiopathic arthritis

PA = Psoriatic arthritis

AS = Ankylosing spondylitis

CD = Crohn’s disease

P = Psoriasis

CLL= Chronic lymphocytic leukaemia

NHL= Non-Hodgkin’s lymphoma

NICEapproval status correct as of July 2011. Please refer to NICEwebsite for latest guidance http://www.nice.org.uk/

Sources:NICE, manufacturers Summaries of Product Characteristics, and BNF vol 61